EDSA — Expected Completion of Clinical Trial for Paridiprubart (NCT06701669)
Feb 8, 2028, 5:00:00 AM UTC
Summary
EDSA expects the completion of its clinical trial for paridiprubart, a potential treatment for acute respiratory distress syndrome (ARDS), on February 8, 2028. The trial, sponsored by PPD Development, LP, is part of a Phase 2 master protocol evaluating host-directed therapeutic candidates for ARDS. With a current enrollment target of 200 participants, the study will assess safety and efficacy through various clinical measures over a 90-day period following treatment. Participants will continue to receive standard ARDS treatments alongside the investigational product or placebo. As of now, the trial status is recruiting.
Company
EDESA BIOTECH INC (EDSA)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
edesabiotech.comSimilar Events
Expected Completion of Clinical Trial NCT06728319
Biodesix, Inc. is expected to complete its multicenter retrospective chart review study, NCT06728319, evaluating the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests on July 31, 2027. This study aims to assess the impact and utility of these blood-based tests in real-world scenarios, utilizing de-identified patient data from 4,000 enrolled participants, with testing index dates at least one year before data collection. The trial is currently in the 'Active, Not Recruiting' status, with a start date of September 19, 2024. Institutional IRB approval and patient consent waivers have been secured for the collection of data during the trial.
Expected Trial CompletionExpected Completion of Clinical Trial NCT06788756
Moleculin Biotech, Inc. expects to complete a clinical trial by August 1, 2030, evaluating L-Annamycin for Injection in combination with Cytarabine Injection as a second-line therapy for adult patients with refractory/relapsed acute myeloid leukemia (AML). The trial is currently in a pivotal phase 2/3 design and aims to determine the optimal dosage of L-Annamycin through two parts. Part A involves assessing the efficacy and safety of two dosage levels compared to placebo, while Part B will focus on confirming the optimal regimen in a larger patient population. The study, which has an estimated enrollment of 334 participants, reflects ongoing efforts to improve treatment outcomes in this challenging patient demographic.
Clinical Trial CompletionExpected Completion of Clinical Trial NCT01701674
The clinical trial NCT01701674, sponsored by the H. Lee Moffitt Cancer Center and Research Institute, is expected to complete on September 8, 2025. This pilot trial investigates the safety and feasibility of administering ipilimumab with lymphodepletion plus adoptive cell transfer and high-dose IL-2 in patients with melanoma. The trial has a small sample size with an enrollment count of 13, and aims to determine if at least 50% of planned doses can be delivered and 60% of participants can be treated successfully. Preliminary results will be exploratory due to the pilot nature and small sample.
clinical trial completionExpected Completion of Clinical Trial NCT06887920
The clinical trial NCT06887920, sponsored by Pauline Kang at The University of New South Wales, is expected to complete on December 1, 2025. The study compares the effects of MiSight 1-Day contact lenses and Acuvue Oasys for presbyopia on myopic children, specifically assessing myopia progression over a year with an enrollment of 72 participants. As JNJ is the related company, the results may influence their product positioning in the pediatric contact lens market.
clinical trials